Where does Takeda Pharmaceutical Company Limited rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Takeda Pharmaceutical Company Limited ranks #675 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Takeda Pharmaceutical Company Limited hold?

Takeda Pharmaceutical Company Limited holds 668 US utility patents granted between 2015 and 2025, spanning 61 technology areas.

What is Takeda Pharmaceutical Company Limited's Innovation Score?

Takeda Pharmaceutical Company Limited has an Innovation Score of 64.7 out of 100 (top 2% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Takeda Pharmaceutical Company Limited focus on?

Takeda Pharmaceutical Company Limited's top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 535 patents, ranking #16 of 6,058 assignees active in that subclass. Grants appear in 61 CPC subclasses total.

Is Takeda Pharmaceutical Company Limited's patent grant rate increasing or decreasing?

Takeda Pharmaceutical Company Limited's recent grant velocity is +4% compared to the prior five-year period (grant years, not application filing dates). The company is maintaining or growing its granted-patent output.

What does claim depth mean for Takeda Pharmaceutical Company Limited's patents?

Takeda Pharmaceutical Company Limited's patents average 13.9 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Takeda Pharmaceutical Company Limited patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Takeda Pharmaceutical Company Limited

USPTO PatentsView assignee record - 668 granted patents across 61 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Takeda ranks #675 of 49,997 tracked US assignees by granted-patent volume, with 668 patents across 61 technology areas.

#675
of 49,997 US assignees by volume: Top 2%
by Innovation Score (64.7/100): 13.9
avg claims per patent: +4%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R675 · Foreign Corporation #675 · 668 grants

GRANTS-MID · TOP-DECILE · PHOTO-FINISH · CPC-WIDE · INNOV-STRONG · CLAIMS-RICH · TYPE-FRNCORP · VEL-FLAT · BOOK-FULL

GRANTS-MID 668 grants
TOP-DECILE #675/49,997
PHOTO-FINISH Socionext
CPC-WIDE A61P · 61 areas
INNOV-STRONG 64.7/100
CLAIMS-RICH 13.9 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-FLAT +4% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Socionext Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Takeda’s 64.7 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 22.5 pts (35%) Velocity 8.9 pts (14%) Breadth 25.0 pts (39%) Claim depth 8.3 pts (13%)

Qualcomm Incorporated · highest

85
International… · near

65
Unity SF · near

65
Kubota · near

65
PPG Industries Ohio · near

65
Takeda Pharmaceutical · this assignee

65
3D Lighting… · lowest

7

What this shows Takeda's Innovation Score is 64.7/100 (top 2% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Takeda?

Each dot is one of Takeda’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Takeda’s own 13.9 claims/patent is at or below the 15.9 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Takeda vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

How Takeda's grant cadence moved

Between 2020–2024, Takeda Pharmaceutical Company Limited received 305 grants versus 294 in 2015–2019 (+4% equal-window velocity, above median growth). Across complete PatentsView years, output peaked in 2024 at 77 grants and bottomed in 2020 at 46. Lead class A61P accounts for 80.1% of the portfolio across 61 subclasses. Volume neighbours: BAE Systems PLC (#671) and Datang Mobile Communications Equipment Co., Ltd. (#679).

Takeda's three-year grant acceleration

From 2019–2021 to 2022–2024, Takeda Pharmaceutical Company Limited moved from 155 to 207 grants (1.33x the prior three-year total, a multiple, not a CAGR). Among 3,296 tracked assignees with ≥100 grants and ≥20 prior-period grants, that multiple ranks #599. See the growth leaderboard.

BAE Systems

669
Kuraray

669
King Abdullah Uni…

669
Socionext

668
Takeda Pharmaceut… ◀

668
thyssenkrupp

665
Groupon

664
Boehringer Ingelh…

662
Datang Mobile Com…

661

What this shows Takeda holds 668 patents at rank #675, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Takeda

By rank, the assignees closest to #675 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Takeda's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Takeda, neither rank-band nor same-CPC leaders (those blocks stay above). In A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…), Takeda ranks #16 of 6,058 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (65 here).

PPG Industries Ohio, Inc. 65 Kubota Corporation 65 Unity Technologies SF 65 International Engine Intellectual Property Company, LLC 65

Similar claim depth

Nearest assignees by average claims per patent (13.9 here).

Andreas Stihl AG & Co. KG 13.9 avg Amdocs Development Limited 13.9 avg Heraeus Quarzglas GMBH & Co. KG 13.9 avg Hangzhou Great Star Tools Co., Ltd. 13.9 avg

Takeda's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

65 Top 2% higher than 98% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Takeda Pharmaceutical Company Limited patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	67	10.0%
2016	62	9.3%
2017	61	9.1%
2018	47	7.0%
2019	57	8.5%
2020	46	6.9%
2021	52	7.8%
2022	60	9.0%
2023	70	10.5%
2024	77	11.5%
2025partial year	69	10.3%

Which technologies does Takeda Pharmaceutical Company Limited patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 535

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 407

C07D - Heterocyclic Compounds 364

C07K - Peptides 116

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 87

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 41

C07C - Acyclic OR Carbocyclic Compounds 39

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 38

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 34

C12Y - Enzymes 31

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 17

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 16

B01J - Chemical OR Physical Processes, e.g. Catalysis OR Colloid CHEMISTRY; Their Relevant Apparatus 15

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 14

A61J - Containers Specially Adapted FOR Medical OR Pharmaceutical PURPOSES; Devices OR Methods Specially Adapted FOR Bringing Pharmaceutical Products Into Particular Physical OR Administering FORMS; Devices FOR Administering Food OR Medicines ORALLY; Baby COMFORTERS; Devices FOR Receiving Spittle 10

Top 15 of 61 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Takeda Pharmaceutical Company Limited's patent record in context - here's where to go next.

Takeda Pharmaceutical Company Limited's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 80.1% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #675 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Takeda Pharmaceutical Company Limited against BAE Systems PLC, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 64.7/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.